Psammocarcinome ovarien et médecine nucléaire

We report three cases of ovarian psammocarcinoma, which is a serous adenocarcinoma having psammoma calcifications. The FDG uptake in the psammomatous lesions is due to the tissular part of the lesion and the technetium-99m labelled agents uptake to its calcified part. Calcifications are detected on CT scans. Therefore, they are relatively simple to diagnose by nuclear medicine which is useful given relatively the better prognosis of the psammomatous ovarian serous carcinoma when compared to the serous one.     

Les essais cliniques en médecine nucléaire

The EU clinical trials directive (2001/20/EC) was published on the 4th April 2001 and was transposed into French law in 2004. This new clinical trial regulation has modified considerably the research area including clinical trials conducted with radiopharmaceutical medicinal products. This new regulation aims at ensuring the protection of the health and safety of clinical trial participants, the ethical soundness and the reliability and robustness of data generated in clinical trials. In practice, the sponsor has to submit a clinical trial application to the Afssaps for authorization and to the concerned Ethics Committee for a positive opinion. The content of the clinical trial application regarding the investigational medicinal product is very detailed and a heavy technical dossier could be required in order to justify the quality of the medicinal product used in the clinical trial. Furthermore, pharmacy and radiopharmacy required specific authorizations for preparing these medicinal products. This new regulation could refrain nuclear medicine from conducting clinical trials.